Serum visfatin levels in obese and non-obese individuals; A comparative cross-sectional study.

Abstract

Objective: To compare serum visfatin levels in obese and non-obese individuals. Study Design: Cross-sectional study. Setting: District Head Quarter Hospital, Gujrat. Period: July 2020 to May 2021. Material & Methods: A total of 52 subjects were included fulfilling the inclusion criteria. They were divided in two groups, 26 non-obese subjects were placed in Group A and 26 obese subjects in Group B. The serum visfatin level, Low-Density Lipoprotein (LDL), High-Density Lipoprotein (HDL), triglycerides (TG) were calculated in both groups. The statistical analysis was carried out using SPSS version 22.0. Results: The obese subjects had higher serum visfatin levels than the non-obese i.e. 3.87 ± 0.90ng/mL vs. 1.08 ± 0.56 ng/mL (p=0.001). A significant elevation was observed in the serum LDL level among obese subjects, 224.6 ± 55.0 mg/dl compared to 114.2 ± 22.9 mg/dl among non-obese subjects. Similarly, the serum TG levels were also significantly high among obese subjects (p=0.001). The intergroup comparison showed that the serum visfatin levels were higher among obese subjects with dyslipidemia (3.97 ± 0.93 ng/dl) than non-obese (3.46 ± 0.86 ng/dl). Conclusion: It is concluded that the serum visfatin levels are significantly high among obese individuals than non-obese counterparts.

Insight on Visfatin as cardiovascular dysfunction metabolic factor (literature review)

“…Адипокіни здатні чинити вплив не лише локально, в межах жирової тканини, а й діяти дистантно і регулювати різноманітні фізіологічні та біохімічні процеси у віддалених органах і тканинах. Зокрема, адипокіни відповідають за контроль маси тіла, апетиту, харчової поведінки, регулюють чутливість клітин-мішеней до дії інсуліну, факторів росту, медіаторів запалення, апоптозу, фіброгенезу [10,12,29]. Родина адипокінів є досить великою і її спектр постійно розширюється.…”